Targeting trojan horse leukocytes for hiv prevention

AIDS

Volumn 24, Issue 2, 2010, Pages 163-187

  Anderson, Deborah J ^a   Politch, Joseph A ^a   Nadolski, Adam M ^a   Blaskewicz, Caitlin D ^a   Pudney, Jeffrey ^a   Mayer, Kenneth H ^b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FENWAY INSTITUTE   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIINFLAMMATORY AGENT; CARBOPOL 974P; CARRAGEENAN; CD4 ANTIBODY; CD8 ANTIGEN; CELLACEFATE; CELLULOSE SULFATE; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYANOVIRIN N; DAPIVIRINE; DENDRIMER; EMTRICITABINE; ENFUVIRTIDE; GLYCEROL MONOLAURATE; HPTN 035; INTEGRIN; INTEGRIN RECEPTOR; MARAVIROC; MICROBICIDE; MIV 150; N [3 [4 (3 BENZYL 1 ETHYL 5 PYRAZOLYL) 1 PIPERIDINYLMETHYL] 4 (3 FLUOROPHENYL)CYCLOPENTYL] N METHYLVALINE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; TENOFOVIR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS DNA; WHI 07;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CELL ISOLATION; CELL MIGRATION; CELL TRANSFER; CELLULAR DISTRIBUTION; CHEMOPROPHYLAXIS; COLUMNAR EPITHELIUM; DENDRITIC CELL; DNA DETERMINATION; DRUG EFFICACY; DRUG SCREENING; ENVIRONMENTAL EXPOSURE; EPITHELIUM CELL; FELINE IMMUNODEFICIENCY VIRUS; FEMALE GENITAL SYSTEM; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFECTION PREVENTION; LANGERHANS CELL; LEUKOCYTE; LEUKOCYTE ADHERENCE; LEUKOCYTE COUNT; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MALE GENITAL SYSTEM; NONHUMAN; POLYMERASE CHAIN REACTION; PRIMATE; PRIORITY JOURNAL; REVIEW; SEMEN ANALYSIS; SEMINAL PLASMA; SEXUAL INTERCOURSE; SEXUAL TRANSMISSION; SIMIAN IMMUNODEFICIENCY VIRUS; SPERMATOCYTE; SPERMATOZOON; SPERMATOZOON MOTILITY; SQUAMOUS EPITHELIUM; T LYMPHOCYTE; TARGET CELL; TRANSCYTOSIS; UTERINE CERVIX; VAGINA MUCOSA; VAGINA SECRETION; VERTICAL TRANSMISSION; VIRUS ATTACHMENT; VIRUS CARRIER; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; CELL ADHESION; CELL MOVEMENT; CERVIX UTERI; FEMALE; GENITALIA; HIV INFECTIONS; HIV-1; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MUCOUS MEMBRANE; SEMEN; VAGINA;

EID: 74249104684     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833424c8     Document Type: Review

References (317)

1. UNAIDS. AIDS epidemic update. Geneva: UNAIDS and WHO; 2007.
2. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003; 1:25-34.
3. Anderson DJ, Yunis EJ. 'Trojan Horse' leukocytes in AIDS. N Engl J Med 1983; 309:984-985.
4. Phillips DM. The role of cell-to-cell transmission in HIV infection. AIDS 1994; 8:719-731.
5. Levy JA. The transmission of AIDS: the case of the infected cell. JAMA 1988; 259:3037-3038.
6. Lehman DA, Farquhar C. Biological mechanisms of vertical human immunodeficiency virus (HIV-1) transmission. Rev Med Virol 2007; 17:381-403. (Pubitemid 350144563)
7. Tuomala RE, O'Driscoll PT, Bremer JW, Jennings C, Xu C, Read JS, et al. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antire-troviral-experienced women. J Infect Dis 2003; 187:375-384.
8. John GC, Nduati RW, Mbori-Ngacha DA, Richardson BA, Panteleeff D, Mwatha A, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183:206-212.
9. Anderson DJ, Pudney J. Mucosal immunology of the human male genital tract and experimental models. In: Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, Mayer L, editors. Mucosal immunology. 3rd ed. New York: Elsevier Academic Press; 2005. pp. 1647-1659.
10. Wolff H, Anderson DJ. Immunohistologic characterization and quantitation of leukocyte subpopulations in human semen. Fertil Steril 1988; 49:497-504.
11. Gil T, Castilla JA, Hortas ML, Redondo M, Samaniego F, Garrido F, et al. Increase of large granular lymphocytes in human ejaculate containing antisperm antibodies. Hum Re-prod 1998; 13:296-301.
12. Tomlinson MJ, Barratt CL, Bolton AE, Lenton EA, Roberts HB, Cooke ID. Round cells and sperm fertilizing capacity: the presence of immature germ cells but not seminal leukocytes are associated with reduced success of in vitro fertilization. Fertil Steril 1992; 58:1257-1259.
13. Denny TN, Scolpino A, Garcia A, Polyak A, Weiss SN, Skurnick JH, et al. Evaluation of T-lymphocyte subsets present in semen and peripheral blood of healthy donors: a report from the heterosexual transmission study.Cytometry 1995; 20:349-355.
14. Ball JK, Curran R, Irving WL, Dearden AA. HIV-1 in semen: determination of proviral and viral titres compared to blood, and quantification of semen leukocyte populations. J Med Virol 1999; 59:356-363.
15. Politch JA, Mayer KH, Anderson DJ. Depletion of CD4R T cells in semen during HIV infection and their restoration following antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 50:283-289
16. WHO. WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction. 3 ed. Cambridge: Cambridge University Press; 1992
17. WHO. WHO laboratory manual for the examination of human semen and sperm-cervical interaction. 4 ed. Cambridge: Cambridge University Press; 1999
18. Tomlinson MJ, White A, Barratt CL, Bolton AE, Cooke ID. The removal of morphologically abnormal sperm forms by phagocytes: a positive role for seminal leukocytes? Hum Reprod 1992; 7:517-522.
19. Yanushpolsky EH, Politch JA, Hill JA, Anderson DJ. Antibiotic therapy and leukocytospermia: a prospective, randomized, controlled study. Fertil Steril 1995; 63:142-147.
20. Politch JA, Tucker L, Bowman FP, Anderson DJ. Concentrations and significance of cytokines and other immunologic factors in semen of healthy fertile men. Hum Reprod 2007; 22:2928-2935.
21. Anderson DJ, Politch JA, O'Brien WX, Xu C, Bowman FP, Mayer KH. Persistent HIV-1 RNA shedding in semen of men on HAART is associated with high risk sexual behavior. In: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2009; Cape Town, South Africa.
22. Wolff H, Anderson DJ. Male genital tract inflammation associated with increased numbers of potential human immunode-ficiencyvirushostcellsinsemen. Andrologia1988;20:404-410.
23. Pudney J, Oneta M, Mayer K, Seage G 3rd, Anderson D. Preejaculatory fluid as potential vector for sexual transmission of HIV-1. Lancet 1992; 340:1470.
24. Ilaria G, Jacobs JL, Polsky B, Koll B, Baron P, MacLow C, et al. Detection of HIV-1 DNA sequences in preejaculatory fluid. Lancet 1992; 340:1469.
25. Donoval BA, Landay AL, Moses S, Agot K, Ndinya-Achola JO, Nyagaya EA, et al. HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol 2006; 125:386-391.
26. McCoombe SG, Short RV. Potential HIV-1 target cells in the human penis. AIDS 2006; 20:1491-1495.
27. Patterson BK, Landay A, Siegel JN, Flener Z, Pessis D, Chaviano A, Bailey RC. Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol 2002; 161:867-873.
28. Van Voorhis BJ, Martinez A, Mayer K, Anderson DJ. Detection of human immunodeficiency virus type 1 in semen from seropositive men using culture and polymerase chain reaction deoxyribonucleic acid amplification techniques. Fertil Steril 1991; 55:588-594.
29. Mermin JH, Holodniy M, Katzenstein DA, Merigan TC. Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. J Infect Dis 1991; 164:769-772.
30. Hamed KA, Winters MA, Holodniy M, Katzenstein DA, Mer-igan TC. Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. J Infect Dis 1993; 167:798-802.
31. Quayle AJ, Xu C, Mayer KH, Anderson DJ. T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis 1997; 176:960-968.
32. Xu C, Politch JA, Tucker L, Mayer KH, Seage GR 3rd, Anderson DJ. Factors associated with increased levels of human immunodeficiency virus type 1 DNA in semen. J Infect Dis 1997; 176:941-947.
33. Zhang H, Dornadula G, Beumont M, Livornese L Jr, Van Uitert B, Henning K, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998; 339:1803-1809.
34. Krieger JN, Nirapathpongporn A, Chaiyaporn M, Peterson G, Nikolaeva I, Akridge R, et al. Vasectomy and human immunodeficiency virus type 1 in semen. J Urol 1998; 159:820-825; discussion 825-826.
35. Mayer KH, Boswell S, Goldstein R, Lo W, Xu C, Tucker L, et al. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin Infect Dis 1999; 28:1252-1259.
36. Tachet A, Dulioust E, Salmon D, De Almeida M, Rivalland S, Finkielsztejn L, et al. Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. AIDS 1999; 13: 823-831.
37. Vernazza PL, Troiani L, Flepp MJ, Cone RW, Schock J, Roth F, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000; 14:117-121.
38. Ghosn J, Viard JP, Katlama C, de Almeida M, Tubiana R, Letourneur F, et al. Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pretreated HIV-infected men. AIDS 2004; 18:447-457.
39. Tindall B, Evans L, Cunningham P, McQueen P, Hurren L, Vasak E, et al. Identification of HIV-1 in semen following primary HIV-1 infection. AIDS 1992; 6:949-952.
40. Atkins MC, Carlin EM, Emery VC, Griffiths PD, Boag F. Fluctuations of HIV load in semen of HIV positive patients with newly acquired sexually transmitted diseases. BMJ 1996; 313:341-342.
41. Ho DD, Schooley RT, Rota TR, Kaplan JC, Flynn T, Salahuddin SZ, et al. HTLV-III in the semen and blood of a healthy homosexual man. Science 1984; 226:451-453.
42. O'Shea S, Cordery M, Barrett WY, Richman DD, Bradbeer C, Banatvala JE. HIV excretion patterns and specific antibody responses in body fluids. J Med Virol 1990; 31:291-296.
43. Krieger JN, Coombs RW, Collier AC, Ross SO, Chaloupka K, Cummings DK, et al. Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy. J Infect Dis 1991; 163:386-388.
44. Krieger JN, Coombs RW, Collier AC, Koehler JK, Ross SO, Chaloupka K, et al. Fertility parameters in men infected with human immunodeficiency virus. J Infect Dis 1991; 164:464-469.
45. Anderson DJ, O'Brien TR, Politch JA, Martinez A, Seage GR 3rd, Padian N, et al. Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. JAMA 1992; 267:2769-2774.
46. Vernazza PL, Eron JJ, Cohen MS, van der Horst CM, Troiani L, Fiscus SA. Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. AIDS 1994; 8:1325-1329.
47. Krieger JN, Coombs RW, Collier AC, Ho DD, Ross SO, Zeh JE, Corey L. Intermittent shedding of human immunodeficiency virus in semen: implications for sexual transmission. J Urol 1995; 154:1035-1040.
48. Dyer JR, Gilliam BL, Eron JJ Jr, Grosso L, Cohen MS, Fiscus SA. Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J Virol Methods 1996; 60:161-170.
49. Vernazza PL, Gilliam BL, Dyer J, Fiscus SA, Eron JJ, Frank AC, Cohen MS. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 1997; 11:987-993.
50. Vernazza PL, Gilliam BL, Flepp M, Dyer JR, Frank AC, Fiscus SA, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997; 11:1249-1254.
51. Coombs RW, Speck CE, Hughes JP, Lee W, Sampoleo R, Ross SO, et al. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis 1998; 177:320-330.
52. Dulioust E, Tachet A, De Almeida M, Finkielsztejn L, Rivalland S, Salmon D, et al. Detection of HIV-1 in seminal plasma and seminal cells of HIV-1 seropositive men. J Reprod Immunol 1998; 41:27-40.
53. NunnariG, OteroM, DornadulaG, VanellaM, ZhangH, Frank I, et al. Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without ongoing cellular infections. AIDS 2002; 16:39-45.
54. Belec L, Georges AJ, Steenman G, Martin PM. Antibodies to human immunodeficiency virus in the semen of heterosexual men. J Infect Dis 1989; 159:324-327. (Pubitemid 19049373)
55. Wolff H, Mayer K, Seage G, Politch J, Horsburgh CR, Anderson D.A comparison of HIV-1 antibody classes, titers, and specificities in paired semen and blood samples from HIV-1 seropositive men. J Acquir Immune Defic Syndr 1992; 5:65-69.
56. Anderson DJ. Genitourinary immune defense. In: Holmes KK, Sparling PF, Piot P, Wasserheit JN, Corey L, Cohen M, editors. Sexually transmitted diseases. 4th ed. New York: McGraw-Hill; 2007.
57. James K, Harvey J, Bradbury AW, Hargreave TB, Cullen RT. The effect of seminal plasma on macrophage function: a possible contributory factor in sexually transmitted disease. AIDS Res 1983; 1:45-57.
58. James K, Hargreave T. Immunosuppression by seminal plasma and its possible clinical significance. Immunol Today 1984; 5:357-363.
59. Allen RD, Roberts TK. Role of spermine in the cytotoxic effects of seminal plasma. Am J Reprod Immunol Microbiol 1987; 13:4-8.
60. Stites DP, Erickson RP. Suppressive effect of seminal plasma on lymphocyte activation. Nature 1975; 253:727-729.
61. Okamoto M, Byrn R, Eyre RC, Mullen T, Church P, Kiessling AA. Seminal plasma induces programmed cell death in cultured peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 2002; 18:797-803.
62. Barratt CL, Harrison PE, Robinson A, Kessopoulou E, Cooke ID. Seminal white blood cells in men with urethral tract infection. A monoclonal antibody study. Br J Urol 1991; 68:531-536.
63. Lomas DA, Natin D, Stockley RA, Shahmanesh M. Chemo-tactic activity of urethral secretions in men with urethritis and the effect of treatment. J Infect Dis 1993; 167:233-236.
64. Eggert-Kruse W, Reuland M, Johannsen W, Strowitzki T, Schlehofer JR. Cytomegalovirus (CMV) infection: related to male and/or female infertility factors? Fertil Steril 2009; 91:67-82.
65. Bezold G, Politch JA, Kiviat NB, Kuypers JM, Wolff H, Anderson DJ. Prevalence of sexually transmissible pathogens in semen from asymptomatic male infertility patients with and without leukocytospermia. Fertil Steril 2007; 87: 1087-1097.
66. Denny TN, Skurnick JH, Garcia A, Perez G, Passannante MR, Colon J, et al. Lymphocyte immunoregulatory cells present in semen from human immunodeficiency virus (HIV)-infected individuals: a report from the HIV Heterosexual Transmission Study. Cytometry 1996; 26:47-51.
67. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:33-42.
68. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75:3-17.
69. Cohen MS, Hoffman IF, Royce RA, Kazembe P, Dyer JR, Daly CC, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997; 349:1868-1873.
70. Dyer JR, Eron JJ, Hoffman IF, Kazembe P, Vernazza PL, Nkata E, et al. Association of CD4 cell depletion and elevated blood and seminal plasma human immunodeficiency virus type 1 (HIV-1) RNA concentrations with genital ulcer disease in HIV-1-infected men in Malawi. J Infect Dis 1998; 177:224-227.
71. Plummer FA, Wainberg MA, Plourde P, Jessamine P, D'Costa LJ, Wamola IA, Ronald AR. Detection of human immunodeficiency virus type 1 (HIV-1) in genital ulcer exudate of HIV-1-infected men by culture and gene amplification. J Infect Dis 1990; 161:810-811.
72. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998; 280:61-66
73. Speck CE, Coombs RW, Koutsky LA, Zeh J, Ross SO, Hooton TM, et al. Risk factors for HIV-1 shedding in semen. Am J Epidemiol 1999; 150:622-631.
74. Comhaire F, Bosmans E, Ombelet W, Punjabi U, Schoonjans F. Cytokines in semen of normal men and of patients with andrological diseases. Am J Reprod Immunol 1994; 31:99-103.
75. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-1409.
76. Pilcher CD, Joaki G, Hoffman IF, Martinson FE, Mapanje C, Stewart PW, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007; 21:1723-1730.
77. Piomboni P, Baccetti B. Spermatozoon as a vehicle for HIV-1 and other viruses:areview.Mol ReprodDev 2000; 56:238-242.
78. Pudney J, Nguyen H, Xu C, Anderson DJ. Microscopic evidence against HIV-1 infection of germ cells or attachment to sperm. J Reprod Immunol 1999; 44:57-77.
79. Quayle AJ, Xu C, Tucker L, Anderson DJ. The case against an association between HIV-1 and sperm: molecular evidence. J Reprod Immunol 1998; 41:127-136. (Pubitemid 29017870)
80. Roulet V, Satie AP, Ruffault A, Le Tortorec A, Denis H, Guist'hau O, et al. Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitro. Am J Pathol 2006; 169:2094-2103.
81. Nuovo GJ, Becker J, Simsir A, Margiotta M, Khalife G, Shev-chuk M. HIV-1 nucleic acids localize to the spermatogonia and their progeny. A study by polymerase chain reaction in situ hybridization. Am J Pathol 1994; 144:1142-1148.
82. Muciaccia B, Filippini A, Ziparo E, Colelli F, Baroni CD, Stefanini M. Testicular germ cells of HIV-seropositive asymptomatic men are infected by the virus. J Reprod Immunol 1998; 41:81-93.
83. Bagasra O, Farzadegan H, Seshamma T, Oakes JW, Saah A, Pomerantz RJ. Detection of HIV-1 proviral DNA in sperm from HIV-1-infected men. AIDS 1994; 8:1669-1674.
84. Baccetti B, Benedetto A, Burrini AG, Collodel G, Elia C, Piom-boni P, et al. HIV particles detected in spermatozoa of patients with AIDS. J Submicrosc Cytol Pathol 1991; 23:339-345.
85. Dussaix E, Guetard D, Dauguet C, D'Almeida M, Auer J, Ellrodt A, et al. Spermatozoa as potential carriers of HIV. Res Virol 1993; 144:487-495.
86. Persico T, Savasi V, Ferrazzi E, Oneta M, Semprini AE, Simoni G. Detection of human immunodeficiency virus-1 RNA and DNA by extractive and in situ PCR in unprocessed semen and seminal fractions isolated by semen-washing procedure. Hum Reprod 2006; 21:1525-1530.
87. Pudney J, Nguyen H, Xu C, Anderson DJ. Microscopic evidence against HIV-1 infection of germ cells or attachment to sperm. J Reprod Immunol 1998; 41:105-125.
88. Kato S, HanabusaH, KanekoS, Takakuwa K, SuzukiM, Kuji N, et al. Complete removal ofHIV-1 RNA and proviral DNA from semen by the swim-up method: assisted reproduction technique using spermatozoa free from HIV-1. AIDS 2006; 20:967-973.
89. Kim LU, Johnson MR, Barton S, Nelson MR, Sontag G, Smith JR, et al. Evaluation of sperm washing as a potential method of reducing HIV transmission in HIV-discordant couples wishing to have children. AIDS 1999; 13:645-651.
90. Politch JA, Xu C, Tucker L, Anderson DJ. Separation of human immunodeficiency virus type 1 from motile sperm by the double tube gradient method versus other methods. Fertil Steril 2004; 81:440-447.
91. Kashima K, TakakuwaK, Suzuki M, MakinoM, Kaneko S, Kato S, et al. Studies of assisted reproduction techniques (ART) for HIV-1-discordant couples using washed sperm and the nested PCR method: a comparison of the pregnancy rates in HIV-1-discordant couples and control couples. Jpn J Infect Dis 2009; 62:173-176.
92. Lasheeb AS, King J, Ball JK, Curran R, Barratt CL, Afnan M, Pillay D. Semen characteristics in HIV-1 positive men and the effect of semen washing. Genitourin Med 1997; 73:303-305.
93. Hanabusa H, Kuji N, Kato S, Tagami H, Kaneko S, Tanaka H, Yoshimura Y. An evaluation of semen processing methods for eliminating HIV-1. AIDS 2000; 14:1611-1616.
94. Chrystie IL, Mullen JE, Braude PR, Rowell P, Williams E, Elkington N, et al. Assisted conception in HIV discordant couples: evaluation of semen processing techniques in reducing HIV viral load. J Reprod Immunol 1998; 41:301-306.
95. Pasquier C, Daudin M, Righi L, Berges L, Thauvin L, Berrebi A, et al. Sperm washing and virus nucleic acid detection to reduce HIV and hepatitis C virus transmission in serodiscordant couples wishing to have children. AIDS 2000; 14:2093-2099.
96. Marina S, Marina F, Alcolea R, Exposito R, Huguet J, Nadal J, Verges A. Human immunodeficiency virus type 1-serodiscor-dant couples can bear healthy children after undergoing intrauterine insemination. Fertil Steril 1998; 70:35-39.
97. Semprini AE, Fiore S, Pardi G. Reproductive counselling for HIV-discordant couples. Lancet 1997; 349:1401-1402.
98. Semprini AE, Levi-Setti P, Bozzo M, Ravizza M, Taglioretti A, Sulpizio P, et al. Insemination of HIV-negative women with processed semen of HIV-positive partners. Lancet 1992; 340:1317-1319.
99. Sauer MV. Sperm washing techniques address the fertility needs of HIV-seropositive men: a clinical review. Reprod Biomed Online 2005; 10:135-140.
100. Sauer MV, Chang PL. Establishing a clinical program for human immunodeficiency virus 1-seropositive men to father seronegative children by means of in vitro fertilization with intracytoplasmic sperm injection. Am J Obstet Gynecol 2002; 186:627-633.
101. Pena JE, Thornton MH, Sauer MV. Complications of in vitro fertilization with intracytoplasmic sperm injection in human immunodeficiency virus serodiscordant couples. Arch Gyne-col Obstet 2003; 268:198-201.
102. Ohl J, Partisani M, Wittemer C, Schmitt MP, Cranz C, Stoll-Keller F, et al. Assisted reproduction techniques for HIV serodiscordant couples: 18 months of experience. Hum Re-prod 2003; 18:1244-1249.
103. Gilling-Smith C, Nicopoullos JD, Semprini AE, Frodsham LC. HIV and reproductive care: a review of current practice. BJOG 2006; 113:869-878.
104. Savasi V, Ferrazzi E, Lanzani C, Oneta M, Parrilla B, Persico T. Safety of sperm washing and ART outcome in 741 HIV-1-serodiscordant couples. Hum Reprod 2007; 22:772-777.
105. Bujan L, Sergerie M, Kiffer N, Moinard N, Seguela G, Merca-dier B, et al. Good efficiency of intrauterine insemination programme for serodiscordant couples with HIV-1 infected male partner: a retrospective comparative study. Eur J Obstet Gynecol Reprod Biol 2007; 135:76-82.
106. Scofield VL. Sperm as infection-potentiating cofactors in HIV transmission. J Reprod Immunol 1998; 41:359-372.
107. Bandivdekar AH, Velhal SM, Raghavan VP. Identification of CD4-independent HIV receptors on spermatozoa. Am J Re-prod Immunol 2003; 50:322-327.
108. Brogi A, Presentini R, Moretti E, Strazza M, Piomboni P, Costantino-Ceccarini E. New insights into the interaction between the gp120 and the HIV receptor in human sperm (human.sperm/gp120/galactoglycerolipid/ antigalactosylcer-amide/seminolip id/spermatogonia). J Reprod Immunol 1998; 41:213-231.
109. Fanibunda SE, Velhal SM, Raghavan VP, Bandivdekar AH. CD4 independent binding of HIV gp120 to mannose receptor on human spermatozoa. J Acquir Immune Defic Syndr 2008; 48:389-397.
110. Gadella BM, Hammache D, Pieroni G, Colenbrander B, van Golde LM, Fantini J. Glycolipids as potential binding sites for HIV: topology in the sperm plasma membrane in relation to the regulation of membrane fusion. J Reprod Immunol 1998; 41:233-253.
111. Cardona-Maya W, Lopez-Herrera A, Velilla-Hernandez P, Rugeles MT, Cadavid AP. The role of mannose receptor on HIV-1 entry into human spermatozoa. Am J Reprod Immunol 2006; 55:241-245.
112. Muciaccia B, Corallini S, Vicini E, Padula F, Gandini L, Liuzzi G, et al. HIV-1 viral DNA is present in ejaculated abnormal spermatozoa of seropositive subjects. Hum Reprod 2007; 22:2868-2878.
113. Sievers-Altermann R, Engelbrecht DV. Entry of spermatozoa into the cervical mucosa and transmission of the AIDS virus. S Afr Med J 1990; 77:319.
114. Wah RM, Anderson DJ, Hill JA. Asymptomatic cervicovaginal leukocytosis in infertile women. Fertil Steril 1990; 54:445-450.
115. Hill JA, Anderson DJ. Human vaginal leukocytes and the effects of vaginal fluid on lymphocyte and macrophage defense functions. Am J Obstet Gynecol 1992; 166:720-726.
116. Bardeguez AD, Skurnick JH, Perez G, Colon JM, Kloser P, Denny TN. Lymphocyte shedding from genital tract of human immunodeficiency virus-infected women: immunophenoty-pic and clinical correlates. Am J Obstet Gynecol 1997; 176:158-165.
117. Anderson DJ, Politch JA, Tucker LD, Fichorova R, Haimovici F, Tuomala RE, Mayer KH. Quantitation of mediators of inflammation and immunity in genital tract secretions and their relevance to HIV type 1 transmission. AIDS Res Hum Retro-viruses 1998; 14 (Suppl 1):S43-S49.
118. Olmsted SS, Khanna KV, Ng EM, Whitten ST, Johnson ON 3rd, Markham RB, et al. Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model. BMC Infect Dis 2005; 5:79.
119. Levine WC, Pope V, Bhoomkar A, Tambe P, Lewis JS, Zaidi AA, et al. Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J Infect Dis 1998; 177:167-174.
120. Eschenbach DA, Hillier S, Critchlow C, Stevens C, DeRouen T, Holmes KK. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol 1988; 158:819-828.
121. Cook RL, Redondo-Lopez V, Schmitt C, Meriwether C, Sobel JD. Clinical, microbiological, and biochemical factors in recurrent bacterial vaginosis. J Clin Microbiol 1992; 30: 870-877.
122. Clemetson DB, Moss GB, Willerford DM, Hensel M, Emonyi W, Holmes KK, et al. Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA 1993; 269:2860-2864.
123. Cowan FF, Pascoe SJ, Barlow KL, Langhaug LF, Jaffar S, Hargrove JW, et al. Association of genital shedding of herpes simplex virus type 2 and HIV-1 among sex workers in rural Zimbabwe. AIDS 2006; 20:261-267.
124. John GC, Nduati RW, Mbori-Ngacha D, et al. Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: association with immunosuppression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency. J Infect Dis 1997; 175:57-62.
125. Kreiss J, Willerford DM, Hensel M, Emonyi W, Plummer F, Ndinya-Achola J, et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Infect Dis 1994; 170:1597-1601.
126. McClelland RS, Wang CC, OverbaughJ, Richardson BA, Corey L, Ashley RL, et al. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002; 16:2425-2430.
127. McClelland RS, Wang CC, Mandaliya K, Overbaugh J, Reiner MT, Panteleeff DD, et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001; 15:105-110.
128. Mostad SB, Kreiss JK, Ryncarz AJ, Mandaliya K, Chohan B, Ndinya-Achola J, et al. Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. J Infect Dis 2000; 181:58-63.
129. Mostad SB, Overbaugh J, DeVange DM, Welch MJ, Chohan B, Mandaliya K, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997; 350:922-927.
130. Spinillo A, Zara F, Gardella B, Preti E, Mainini R, Maserati R. The effect of vaginal candidiasis on the shedding of human immunodeficiency virus in cervicovaginal secretions. Am J Obstet Gynecol 2005; 192:774-779.
131. Spinillo A, Debiaggi M, Zara F, Maserati R, Polatti F, De Santolo A. Factors associated with nucleic acids related to human immunodeficiency virus type 1 in cervico-vaginal secretions. BJOG 2001; 108:634-641.
132. Wang CC, McClelland RS, Reilly M, Overbaugh J, Emery SR, Mandaliya K, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001; 183:1017-1022.
133. Manhart LE, Mostad SB, Baeten JM, Astete SG, Mandaliya K, Totten PA. High mycoplasma genitalium organism burden is associated with shedding of HIV-1 DNA from the cervix. J Infect Dis 2008; 197:733-736.
134. Wang CC, McClelland RS, Overbaugh J, Reilly M, Panteleeff DD, Mandaliya K, et al. The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS 2004; 18:205-209.
135. Baeten JM, McClelland RS, Richardson BA, Bankson DD, Lavreys L, Wener MH, et al. Vitamin A deficiency and the acute phase response among HIV-1-infected and-uninfected women in Kenya. J Acquir Immune Defic Syndr 2002; 31:243-249
136. Baeten JM, Mostad SB, Hughes MP, Overbaugh J, Bankson DD, Mandaliya K, et al. Selenium deficiency is associated with shedding of HIV-1-infected cells in the female genital tract. J Acquir Immune Defic Syndr 2001; 26:360-364.
137. McClelland RS, Baeten JM, Overbaugh J, Richardson BA, Mandaliya K, Emery S, et al. Micronutrient supplementation increases genital tract shedding of HIV-1 in women: results of a randomized trial. J Acquir Immune Defic Syndr 2004; 37:1657-1663. (Pubitemid 39658209)
138. Graham SM, Holte SE, Peshu NM, Richardson BA, Panteleeff DD, Jaoko WG, et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007; 21:501-507.
139. Nunnari G, Sullivan J, Xu Y, Nyirjesy P, Kulkosky J, Cavert W, et al. HIV type 1 cervicovaginal reservoirs in the era of HAART. AIDS Res Hum Retroviruses 2005; 21:714-718. (Pubitemid 41254237)
140. Panther LA, Tucker L, Xu C, Tuomala RE, Mullins JI, Anderson DJ. Genital tract human immunodeficiency virus type 1 (HIV-1) shedding and inflammation and HIV-1 env diversity in perinatal HIV-1 transmission. J Infect Dis 2000; 181:555-563.
141. Mbopi-Keou FX, Gresenguet G, Mayaud P, Weiss HA, Gopal R, Matta M, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000; 182:1090-1096.
142. Iversen AK, Larsen AR, Jensen T, Fugger L, Balslev U, Wahl S, et al. Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions. J Infect Dis 1998; 177:1214-1220.
143. Debiaggi M, Zara F, Spinillo A, De Santolo A, Maserati R, Bruno R, et al. Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2001; 20:91-96.
144. Benki S, McClelland RS, Emery S, Baeten JM, Richardson BA, Lavreys L, et al. Quantification of genital human immunodeficiency virus type 1 (HIV-1) DNA in specimens from women with low plasma HIV-1 RNA levels typical of HIV-1 non-transmitters. J Clin Microbiol 2006; 44:4357-4362.
145. Andreoletti L, Chomont N, Gresenguet G, Matta M, de Dieu Longo J, Carreno MP, et al. Independent levels of cell-free and cell-associated human immunodeficiency virus-1 in genital-tract secretions of clinically asymptomatic, treatment-naive African women. J Infect Dis 2003; 188:549-554.
146. Zara F, Nappi RE, Brerra R, Migliavacca R, Maserati R, Spinillo A. Markers of local immunity in cervico-vaginal secretions of HIV infected women: implications for HIV shedding. Sex Transm Infect 2004; 80:108-112.
147. Henin Y, Mandelbrot L, Henrion R, Pradinaud R, Coulaud JP, Montagnier L. Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women. J Acquir Immune Defic Syndr 1993; 6:72-75. (Pubitemid 23039262)
148. Vogt MW, Witt DJ, Craven DE, Byington R, Crawford DF, Hutchinson MS, et al. Isolation patterns of the human immunodeficiency virus from cervical secretions during the menstrual cycle of women at risk for the acquired immunodeficiency syndrome. Ann Intern Med 1987; 106:380-382.
149. Vogt MW, Witt DJ, Craven DE, Byington R, Crawford DF, Schooley RT, Hirsch MS. Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS. Lancet 1986; 1:525-527.
150. Wofsy CB, Cohen JB, Hauer LB, Padian NS, Michaelis BA, Evans LA, Levy JA. Isolation of AIDS-associated retrovirus from genital secretions of women with antibodies to the virus. Lancet 1986; 1:527-529.
151. Saracino A, Di Stefano M, Fiore JR, Lepera A, Raimondi D, Angarano G, Pastore G. Frequent detection of HIV-1 RNA but low rates of HIV-1 isolation in cervicovaginal secretions from infected women. New Microbiol 2000; 23:79-83.
152. Cummins JE Jr, Villanueva JM, Evans-Strickfaden T, Sesay SM, Abner SR, Bush TJ, et al. Detection of infectious human immunodeficiency virus type 1 in female genital secretions by a short-term culture method. J Clin Microbiol 2003; 41:4081-4088.
153. Hillier SL. Normal genital flora. In: Holmes KK, Sparling PF, Stamm W, et al. editors. Sexually transmitted diseases. 4th ed. New York: McGraw Hill Medical Publications; 2008. pp. 298-308.
154. Parkhurst MR, Saltzman WM. Leukocytes migrate through three-dimensional gels of midcycle cervical mucus. Cell Immunol 1994; 156:77-94.
155. Masters WH, Johnson VE. The artificial vagina: anatomic, physiologic, psychosexual function. West J Surg Obstet Gy-necol 1961; 69:192-212.
156. Masters WH, Johnson VE. The physiology of the vaginal reproductive function. West J Surg Obstet Gynecol 1961; 69:105-120.
157. Pearce-Pratt R, Phillips DM. Studies of adhesion of lympho-cytic cells: implications for sexual transmission of human immunodeficiency virus. Biol Reprod 1993; 48:431-445. (Pubitemid 23056005)
158. Tan X, Phillips DM. Cell-mediated infection of cervix derived epithelial cells with primary isolates of human immunodeficiency virus. Arch Virol 1996; 141:1177-1189.
159. Dezzutti CS, Guenthner PC, Cummins JE Jr, Cabrera T, Marshall JH, Dillberger A, Lal RB. Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J Infect Dis 2001; 183:1204-1213.
160. Maher D, Wu X, Schacker T, Horbul J, Southern P. HIV binding, penetration, and primary infection in human cervi-covaginal tissue. Proc Natl Acad Sci U S A 2005; 102:11504-11509.
161. Wu Z, Chen Z, Phillips DM. Human genital epithelial cells capture cell-free human immunodeficiency virus type 1 and transmit the virus to CD4R Cells: implications for mechanisms of sexual transmission. J Infect Dis 2003; 188:1473-1482.
162. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458:1034-1038.
163. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997; 3:42-47.
164. Alfsen A, Yu H, Magerus-Chatinet A, Schmitt A, Bomsel M. HIV-1-infected blood mononuclear cells form an integrin-and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer. Mol Biol Cell 2005; 16:4267-4279.
165. Pudney J, Anderson DJ. Immunobiology of the human penile urethra. Am J Pathol 1995; 147:155-165.
166. Pudney J, Quayle AJ, Anderson DJ. Immunological microen-vironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 2005; 73:1253-1263.
167. Howell AL, Edkins RD, Rier SE, Yeaman GR, Stern JE, Fanger MW, Wira CR. Human immunodeficiency virus type 1 infection of cells and tissues from the upper and lower human female reproductive tract. J Virol 1997; 71:3498-3506.
168. Phillips DM, Zacharopoulos VR. Nonoxynol-9 enhances rectal infection by herpes simplex virus in mice. Contraception 1998; 57:341-348.
169. Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 184:418-428.
170. Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F. In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr 2005; 39:1-8.
171. Stafford MK, Ward H, Flanagan A, Rosenstein IJ, Taylor-Robinson D, Smith JR, et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:327-331.
172. Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA. Seminal plasma differentially regulates inflammatory cyto-kine gene expression in human cervical and vaginal epithelial cells. Mol Hum Reprod 2007; 13:491-501.
173. Thompson LA, Barratt CL, Bolton AE, Cooke ID. The leuko-cytic reaction of the human uterine cervix. Am J Reprod Immunol 1992; 28:85-89.
174. Moore JP, Shattock RJ. Preventing HIV-1 sexual transmission: not sexy enough science, or no benefit to the bottom line? J Antimicrob Chemother 2003; 52:890-892.
175. Frost SD, Liu Y, Pond SL, Chappey C, Wrin T, Petropoulos CJ, et al. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol 2005; 79:6523-6527. (Pubitemid 40617256)
176. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 2005; 102:18514-18519. (Pubitemid 43011257)
177. Gottlieb GS, Heath L, Nickle DC, Wong KG, Leach SE, Jacobs B, et al. HIV-1 variation before seroconversion in men who have sex with men: analysis of acute/early HIV infection in the multicenter AIDS cohort study. J Infect Dis 2008; 197:1011-1015.
178. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261:1179-1181.
179. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Brown AJ, Simmonds P. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993; 67:3345-3356.
180. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004; 303:2019-2022.
181. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008; 105:7552-7557.
182. Sagar M, Laeyendecker O, Lee S, Gamiel J, Wawer MJ, Gray RH, et al. Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J Infect Dis 2009; 199:580-589.
183. Long EM, Martin HL Jr, Kreiss JK, Rainwater SM, Lavreys L, Jackson DJ, et al. Gender differences in HIV-1 diversity at time of infection. Nat Med 2000; 6:71-75.
184. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009; 5: e1000274.
185. Ritola K, Pilcher CD, Fiscus SA, Hoffman NG, Nelson JA, Kitrinos KM, et al. Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol 2004; 78:11208-11218.
186. Sagar M, Kirkegaard E, Long EM, Celum C, Buchbinder S, Daar ES, Overbaugh J. Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol 2004; 78:7279-7283.
187. Pillai SK, GoodB, Pond SK, Wong JK, Strain MC, Richman DD, Smith DM. Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol 2005; 79:1734-1742.
188. Ping LH, Cohen MS, Hoffman I, Vernazza P, Seillier-Moisei-witsch F, Chakraborty H, et al. Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. J Virol 2000; 74:8946-8952.
189. Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, Cooper DA, Ho DD. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996; 70:3098-3107.
190. Byrn RA, Zhang D, Eyre R, McGowan K, Kiessling AA. HIV-1 in semen: an isolated virus reservoir. Lancet 1997; 350:1141.
191. Delwart EL, Mullins JI, Gupta P, Learn GH Jr, Holodniy M, Katzenstein D, et al. Human immunodeficiency virus type 1 populations in blood and semen. J Virol 1998; 72:617-623. (Pubitemid 28048879)
192. Paranjpe S, Craigo J, Patterson B, Ding M, Barroso P, Harrison L, et al. Subcompartmentalization of HIV-1 quasispecies between seminal cells and seminal plasma indicates their origin in distinct genital tissues. AIDS Res Hum Retroviruses 2002; 18:1271-1280.
193. Peters B, Whittall T, Babaahmady K, Gray K, Vaughan R, Lehner T. Effect of heterosexual intercourse on mucosal alloimmunisation and resistance to HIV-1 infection. Lancet 2004; 363:518-524.
194. Anderson DJ, Bach DL, Yunis EJ, DeWolf WC. Major histo-compatibility antigens are not expressed on human epididy-mal sperm. J Immunol 1982; 129:452-454.
195. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, Neutra MR. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 2002; 169:566-574.
196. Burkhard MJ, Dean GA. Transmission and immunopathogen-esis of FIV in cats as a model for HIV. Curr HIV Res 2003; 1:15-29.
197. Bendinelli M, Pistello M, Lombardi S, Poli A, Garzelli C, Matteucci D, et al. Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev 1995; 8:87-112.
198. Gardner MB, Luciw PA. Animal models of AIDS. FASEB J 1989; 3:2593-2606.
199. Moench TR, Whaley KJ, Mandrell TD, Bishop BD, Witt CJ, Cone RA. The cat/feline immunodeficiency virus model for transmucosal transmission of AIDS: nonoxynol-9 contraceptive jelly blocks transmission by an infected cell inoculum. AIDS 1993; 7:797-802.
200. Bishop SA, Stokes CR, Gruffydd-Jones TJ, Whiting CV, Harbour DA. Vaginal and rectal infection of cats with feline immunodeficiency virus. Vet Microbiol 1996; 51:217-227.
201. D'Cruz OJ, Waurzyniak B, Uckun FM. Antiretroviral spermi-cide WHI-07 prevents vaginal and rectal transmission of feline immunodeficiency virus in domestic cats. Antimicrob Agents Chemother 2004; 48:1082-1088.
202. Lecollinet S, Richardson J. Vaccination against the feline immunodeficiency virus: the road not taken. Comp Immunol Microbiol Infect Dis 2008; 31:167-190.
203. Yamamoto JK, Pu R, Sato E, Hohdatsu T. Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine. AIDS 2007; 21:547-563. (Pubitemid 46303648)
204. Ibata B, Parr EL, King NJ, Parr MB. Migration of foreign lymphocytes from the mouse vagina into the cervicovaginal mucosa and to the iliac lymph nodes. Biol Reprod 1997; 56:537-543.
205. Zacharopoulos VR, Perotti ME, Phillips DM. A role for cell migration in the sexual transmission of HIV-1? Curr Biol 1997; 7:534-537.
206. Di Fabio S, Giannini G, Lapenta C, Spada M, Binelli A, Germinario E, et al. Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. AIDS 2001; 15:2231-2238.
207. Khanna KV, Whaley KJ, Zeitlin L, Moench TR, Mehrazar K, Cone RA, et al. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J Clin Invest 2002; 109:205-211.
208. D'Cruz OJ, Uckun FM. Limitations of the human-PBL-SCID mouse model for vaginal transmission of HIV-1. Am J Reprod Immunol 2007; 57:353-360.
209. Berges BK, Akkina SR, Folkvord JM, Connick E, Akkina R. Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2S/S gammac S/S (RAG-hu) mice. Virology 2008; 373:342-351.
210. Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, et al. Antiretroviral preexposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008; 5:e16.
211. Hofer U, Baenziger S, Heikenwalder M, Schlaepfer E, Gehre N, Regenass S, et al. RAG2S/S gamma(c)S/S mice transplanted with CD34R cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus. J Virol 2008; 82:12145-12153.
212. Girard M, Mahoney J, Wei Q, van der Ryst E, Muchmore E, Barre-Sinoussi F, Fultz PN. Genital infection of female chimpanzees with human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1998; 14:1357-1367. (Pubitemid 28465270)
213. SodoraDL, GettieA, Miller CJ, Marx PA. Vaginaltransmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Hum Retroviruses 1998; 14 (Suppl 1):S119-S123.
214. Weiler AM, Li Q, Duan L, Kaizu M, Weisgrau KL, Friedrich TC, et al. Genital ulcers facilitate rapid viral entry and dissemination following intravaginal inoculation with cell-associated simian immunodeficiency virus SIVmac239. J Virol 2008; 82:4154-4158.
215. Kaizu M, Weiler AM, Weisgrau KL, Vielhuber KA, May G, Piaskowski SM, et al. Repeated intravaginal inoculation with cell-associated simian immunodeficiency virus results in persistent infection of nonhuman primates. J Infect Dis 2006; 194:912-916.
216. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005; 79:9217-9227.
217. LeGrand R. Infection of macaques after vaginal exposure to cell-associated SIV. Microbicides 2008. New Delhi, India; 2008.
218. Cohen MS, Pilcher CD. Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis 2005; 191:1391-1393.
219. Tan X, Pearce-Pratt R, Phillips DM. Productive infection of a cervical epithelial cell line with human immunodeficiency virus: implications for sexual transmission. J Virol 1993; 67:6447-6452.
220. Chancey CJ, Khanna KV, Seegers JF, Zhang GW, Hildreth J, Langan A, Markham RB. Lactobacilli-expressed single-chain variable fragment (scFv) specific for intercellular adhesion molecule 1 (ICAM-1) blocks cell-associated HIV-1 transmission across a cervical epithelial monolayer. J Immunol 2006; 176:5627-5636.
221. Van Herrewege Y, Michiels J, Waeytens A, De Boeck G, Salden E, Heyndrickx L, et al. A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides. Antiviral Res 2007; 74:111-124.
222. TudorD, DerrienM, Diomede L, Drillet AS, HouimelM, Moog C, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(R) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009; 2:412-426.
223. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000; 74:5577-5586.
224. Bobardt MD, Chatterji U, Selvarajah S, Van der Schueren B, David G, Kahn B, Gallay PA. Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J Virol 2007; 81:395-405.
225. Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, Shattock RJ. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J Gen Virol 2009; 90:234-243.
226. Collins KB, Patterson BK, Naus GJ, Landers DV, Gupta P. Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat Med 2000; 6:475-479.
227. Blaskewicz C, Nadolski A, Pudney J, Ayehunie S, Anderson DJ. Role of integrin receptors and junctional proteins in macro-phage migration through a vaginal epithelial tissue model. In: 14th International Congress of Mucosal Immunology; 2009; Boston, Massachusetts, USA.
228. Shieh CC, Sadasivan BK, Russell GJ, Schon MP, Parker CM, Brenner MB. Lymphocyte adhesion to epithelia and endothe-lia mediated by the lymphocyte endothelial-epithelial cell adhesion molecule glycoprotein. J Immunol 1999; 163:1592-1601.
229. Pearce-Pratt R, Phillips DM. Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol Reprod 1996; 54:173-182.
230. Evans R, Patzak I, Svensson L, De Filippo K, JonesK, McDowall A, Hogg N. Integrins in immunity. J Cell Sci 2009; 122:215-225.
231. Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, Grabovsky V, et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(R) cells: role in transendothelial/stromal migration and engraftment of NOD/ SCID mice. Blood 2000; 95:3289-3296.
232. Parr MB, Parr EL. Interferon-gamma up-regulates intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 and recruits lymphocytes into the vagina of immune mice challenged with herpes simplex virus-2. Immunology 2000; 99:540-545.
233. Carreno MP, Chomont N, Kazatchkine MD, Irinopoulou T, Krief C, Mohamed AS, et al. Binding of LFA-1 (CD11a) to intercellular adhesion molecule 3 (ICAM-3; CD50) and ICAM-2 (CD102) triggers transmigration of human immunodeficiency virus type 1-infected monocytes through mucosal epithelial cells. J Virol 2002; 76:32-40.
234. Wang JH, Kwas C, Wu L. Intercellular adhesion molecule 1 (ICAM-1), but not ICAM-2 and-3, is important for dendritic cell-mediated human immunodeficiency virus type 1 transmission. J Virol 2009; 83:4195-4204.
235. Sanders RW, de Jong EC, Baldwin CE, Schuitemaker JH, Kapsenberg ML, Berkhout B. Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J Virol 2002; 76:7812-7821.
236. Dunehoo AL, Anderson M, Majumdar S, Kobayashi N, Berk-land C, Siahaan TJ. Cell adhesion molecules for targeted drug delivery. J Pharm Sci 2006; 95:1856-1872.
237. Severson EA, Jiang L, Ivanov AI, Mandell KJ, Nusrat A, Parkos CA. Cis-dimerization mediates function of junctional adhesion molecule A. Mol Biol Cell 2008; 19:1862-1872.
238. Zen K, Babbin BA, Liu Y, Whelan JB, Nusrat A, Parkos CA. JAM-C is a component of desmosomes and a ligand for CD11b/CD18-mediated neutrophil transepithelial migration. Mol Biol Cell 2004; 15:3926-3937.
239. Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, Nixon DF. Trafficking of human immunodeficiency virus type 1-specific CD8R T cells to gut-associated lymphoid tissue during chronic infection. J Virol 2003; 77:5621-5631.
240. Schon MP, Arya A, Murphy EA, Adams CM, Strauch UG, Agace WW, et al. Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice. J Immunol 1999; 162:6641-6649.
241. Higgins JM, Mandlebrot DA, Shaw SK, Russell GJ, Murphy EA, Chen YT, et al. Direct and regulated interaction of integrin alphaEbeta7 with E-cadherin. J Cell Biol 1998; 140:197-210.
242. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008; 9:301-309.
243. Quayle AJ, Kourtis AP, Cu-Uvin S, Politch JA, Yang H, Bowman FP, et al. T-lymphocyte profile and total and virus-specific immunoglobulin concentrations in the cervix of HIV-1-infected women. J Acquir Immune Defic Syndr 2007; 44:292-298.
244. Harmsen AG, Muggenburg BA, Snipes MB, Bice DE. The role of macrophages in particle translocation from lungs to lymph nodes. Science 1985; 230:1277-1280.
245. Wells CL, Maddaus MA, Simmons RL. Role of the macrophage in the translocation of intestinal bacteria. Arch Surg 1987; 122:48-53.
246. Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26:257-270.
247. Spira AI, Marx PA, Patterson BK, Mahoney J, Koup RA, Wo-linsky SM, Ho DD. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996; 183:215-225.
248. Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4R T cells. Science 1999; 286:1353-1357.
249. Fichorova RN, Anderson DJ. Differential expression of im-munobiological mediators by immortalized human cervical and vaginal epithelial cells. Biol Reprod 1999; 60:508-514.
250. Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L. Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev 2005; 206:306-335.
251. Maxion HK, Kelly KA. Chemokine expression patterns differ within anatomically distinct regions of the genital tract during Chlamydia trachomatis infection. Infect Immun 2002; 70:1538-1546.
252. Herold S, von Wulffen W, Steinmueller M, Pleschka S, Kuziel WA, Mack M, et al. Alveolar epithelial cells direct monocyte transepithelial migration upon influenza virus infection: impact of chemokines and adhesion molecules. J Immunol 2006; 177:1817-1824.
253. Rasmussen SJ, Eckmann L, Quayle AJ, Shen L, Zhang YX, Anderson DJ, et al. Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Invest 1997; 99:77-87. (Pubitemid 27058297)
254. Wira CR, Fahey JV. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 2008; 22:1909-1917.
255. Davis DM. Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response. Nat Rev Immunol 2007; 7:238-243.
256. Jolly C, Sattentau QJ. Retroviral spread by induction of vir-ological synapses. Traffic 2004; 5:643-650.
257. Piguet V, Sattentau Q. Dangerous liaisons at the virological synapse. J Clin Invest 2004; 114:605-610.
258. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 2004; 199:283-293.
259. Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, et al. The immunological synapse. Annu Rev Immunol 2001; 19:375-396.
260. Dustin ML, Cooper JA. The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling. Nat Immunol 2000; 1:23-29.
261. Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, Griffiths GM, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003; 299:1713-1716.
262. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003; 300:1295-1297.
263. Sherer NM, Lehmann MJ, Jimenez-Soto LF, Horensavitz C, Pypaert M, Mothes W. Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission. Nat Cell Biol 2007; 9:310-315.
264. Sowinski S, Jolly C, Berninghausen O, Purbhoo MA, Chauveau A, Kohler K, et al. Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat Cell Biol 2008; 10:211-219.
265. Perotti ME, Pirovano A, Phillips DM. Carrageenan formulation prevents macrophage trafficking from vagina: implications for microbicide development. Biol Reprod 2003; 69:933-939.
266. Di Fabio S, Van Roey J, Giannini G, van den Mooter G, Spada M, Binelli A, et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the nonnucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003; 17:1597-1604.
267. Matteucci D, Pistello M, Mazzetti P, Giannecchini S, Isola P, Merico A, et al. AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus. Vaccine 1999; 18:119-130.
268. Willits RK, Saltzman WM. The effect of synthetic polymers on the migration of monocytes through human cervical mucus. Biomaterials 2004; 25:4563-4571.
269. Matoba N, Magerus A, Geyer BC, Zhang Y, Muralidharan M, Alfsen A, et al. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc Natl Acad Sci U S A 2004; 101:13584-13589.
270. Hocini H, Belec L, Iscaki S, Garin B, Pillot J, Becquart P, Bomsel M. High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res Hum Retroviruses 1997; 13:1179-1185.
271. Hocini H, Bomsel M. Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by transcytosis in a process impaired by mucosal immunoglo-bulins. J Infect Dis 1999; 179 (Suppl 3):S448-S453.
272. BomselM, HeymanM, HociniH, LagayeS, BelecL, Dupont C, Desgranges C. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998; 9:277-287.
273. Chomont N, Hocini H, Gody JC, Bouhlal H, Becquart P, Krief-Bouillet C, et al. Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. Virology 2008; 370:246-254.
274. Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR. Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis 2006; 6:90.
275. Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoa-ko M, Boakye AY, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2007; 2:e1312.
276. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008; 3:e1474.
277. Karim SA, Colletti A, Richardson B, et al. Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PRO2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial. In: 16th Conference on Retro-viruses and Opportunistic Infections; 2009; Montreal, Canada.
278. Chang TL, Chang CH, Simpson DA, XuQ, Martin PK, Lagenaur LA, et al. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A 2003; 100:11672-11677.
279. Pusch O, Kalyanaraman R, Tucker LD, Wells JM, Ramratnam B, Boden D. An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli. AIDS 2006; 20:1917-1922.
280. Liu X, Lagenaur LA, Lee PP, Xu Q. Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules. Appl Environ Microbiol 2008; 74:4626-4635.
281. Kremer J, Jager S. The significance of antisperm antibodies for sperm-cervical mucus interaction. Hum Reprod 1992; 7:781-784.
282. Whaley KJ, Zeitlin L. Preventing transmission: plant-derived microbicides and mucosal vaccines for reproductive health. Vaccine 2005; 23:1819-1822.
283. Isojima S. Sperm and seminal plasma antigens relevant to contraceptive vaccine development. Curr Opin Immunol 1989; 2:752-756.
284. Scordi-Bello IA, Mosoian A, He C, Chen Y, Cheng Y, Jarvis GA, et al. Candidate sulfonated and sulfated topical microbicides: comparison of antihuman immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother 2005; 49:3607-3615.
285. Romer D, Brighty DW, Robson CL, Sattentau QJ. Candidate polyanionic microbicides inhibit human T-cell lymphotropic virus type 1 receptor interactions, cell-free infection, and cell-cell spread. Antimicrob Agents Chemother 2009; 53:678-687.
286. Fletcher PS, Wallace GS, Mesquita PM, Shattock RJ. Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. Retrovirology 2006; 3:46.
287. Patton DL, Cosgrove Sweeney YT, McCarthy TD, Hillier SL. Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob Agents Chemother 2006; 50: 1696-1700.
288. Mumper RJ, Bell MA, Worthen DR, Cone RA, Lewis GR, Paull JR, Moench TR. Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of action. Drug Dev Ind Pharm 2009; 35:515-524.
289. Witvrouw M, Fikkert V, Pluymers W, Matthews B, Mardel K, Schols D, et al. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Mol Pharmacol 2000; 58:1100-1108.
290. Jiang YH, Emau P, Cairns JS, Flanary L, Morton WR, McCarthy TD, Tsai CC. SPL7013 gel as a topical micro-bicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2005; 21:207-213.
291. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438:99-102.
292. Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, et al. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis 2006; 193:27-35.
293. Teleshova N, Chang T, Profy A, Klotman ME. Inhibitory effect of PRO 2000, a candidate microbicide, on dendritic cell-mediated human immunodeficiency virus transfer. Antimi-crob Agents Chemother 2008; 52:1751-1758.
294. Sachdev DD, Zerhouni-Layachi B, Ortigoza M, Profy AT, Tuen M, Hioe CE, Klotman ME. The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes. J Acquir Immune Defic Syndr 2009; 51:125-129.
295. Lederman MM, Jump R, Pilch-Cooper HA, Root M, Sieg SF. Topical application of entry inhibitors as 'virustats' to prevent sexual transmission of HIV infection. Retrovirology 2008; 5:116.
296. Princen K, Schols D. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth Factor Rev 2005; 16:659-677.
297. Veazey RS, Ling B, Green LC, Ribka EP, Lifson JD, Piatak M Jr, et al. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J Infect Dis 2009; 199:1525-1527.
298. GenescaM, McChesney MB, Miller CJ. Antiviral CD8RTcells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J Intern Med 2009; 265:67-77.
299. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-104.
300. Lehner T, Shearer GM, Hackett CJ, Schultz A, Sharma OK. Alloimmunization as a strategy for vaccine design against HIV/AIDS. AIDS Res Hum Retroviruses 2000; 16: 309-313.
301. Wang Y, Abel K, Lantz K, Krieg AM, McChesney MB, Miller CJ. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravag-inally to rhesus macaques. J Virol 2005; 79:14355-14370.
302. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtrici-tabine and tenofovir. PLoS Med 2008; 5:e28.
303. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local preexposure application of tenofovir gel. PLoS Med 2008; 5:e157; discussion e157.
304. Kunjara-Na-Ayudhya R, Hopkins N, Cost M, Billitto N, Roo-ney J, Dezzutti CS. Microbicide, tenofovir 1% gel, efficacy determined for pre and postcoital use. In: Conference on Retroviruses and Opportunistic Infections; 2009; Montreal, Canada.
305. Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, Martin A, et al. Complete protection from repeated vaginal SHIV Exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 2009; 83:10358-10365.
306. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and unin-fected women. AIDS 2006; 20:543-551.
307. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007; 2:e27.
308. Fletcher P, Harman S, Azijn H, Armanasco N, Manlow P, Perumal D, et al. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2009; 53:487-495.
309. Romano J. Multiple dosage forms of the NNRTI microbicide dapivirine: product development and evaluation. Retrovirol-ogy 2006; 3:S54.
310. Fletcher P, Kiselyeva Y, Wallace G, Romano J, Griffin G, Margolis L, Shattock R. The nonnucleoside reverse tran-scriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol 2005; 79: 11179-11186.
311. Hossain MM, Parniak MA. In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1. J Virol 2006; 80:4440-4446.
312. Yang H, Parniak MA, Isaacs CE, Hillier SL, Rohan LC. Characterization of cyclodextrin inclusion complexes of the anti-HIV nonnucleoside reverse transcriptase inhibitor UC781. AAPS J 2008; 10:606-613.
313. PattonDL, SweeneyYT, BalkusJE, RohanLC, Moncla BJ, Parniak MA, Hillier SL. Preclinical safety assessments of UC781 antihu-man immunodeficiencyvirus topicalmicrobicideformulations. Antimicrob Agents Chemother 2007; 51:1608-1615.
314. Liu S, Lu H, Neurath AR, Jiang S. Combination of candidate microbicides cellulose acetate 1, 2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother 2005; 49:1830-1836.
315. Fernandez-Romero JA, Thorn M, Turville SG, Titchen K, Sudol K, Li J, et al. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis 2007; 34:9-14.
316. Klasse PJ, Shattock R, Moore JP. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008; 59:455-471.
317. Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis 2008; 8:685-697.